A Phase II Trial of Buparlisib in Patients with Platinum-Resistant Metastatic Urothelial Carcinoma

PI3K pathway inhibition with buparlisib exhibited modest activity in metastatic urothelial carcinoma with significant toxicity. Further studies of PI3K pathway inhibition should focus on patients with select genetic alterations and using isoform-selective inhibitors.

Saved in:
Bibliographic Details
Published in:Cancer 2020-08, Vol.126 (20), p.4532-4544
Main Authors: McPherson, Victor, Reardon, Brendan, Bhayankara, Aravind, Scott, Sasinya N., Boyd, Mariel E., Garcia-Grossman, Ilana R., Regazzi, Ashley M., McCoy, Asia S., Kim, Philip H., Al-Ahmadie, Hikmat, Ostrovnaya, Irina, Roth, Andrew J., Farooki, Azeez, Berger, Michael F., Rosenberg, Jonathan E., Solit, David B., Van Allen, Eliezer, Milowsky, Matthew I, Bajorin, Dean F., Iyer, Gopa
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PI3K pathway inhibition with buparlisib exhibited modest activity in metastatic urothelial carcinoma with significant toxicity. Further studies of PI3K pathway inhibition should focus on patients with select genetic alterations and using isoform-selective inhibitors.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.33071